ProQR Therapeutics N.V.

ProQR Therapeutics N.V. is a biopharmaceutical company that is focused on the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. The company was founded in 2012 and is headquartered in Leiden, the Netherlands. ProQR’s lead product candidate, sepofarsen, is in phase II/III clinical trial Illuminate Trial for the treatment of Leber Congenital Amaurosis 10 disease. It is also developing ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. Additionally, ProQR is developing its Axiomer RNA base-editing platform technology. To support its research and development, ProQR has established a number of partnerships and collaborations. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. It also has a license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR is also pursuing various other collaborations with academic and industrial partners to advance its research and development pipeline. The company is committed to developing innovative therapies that can make a meaningful difference in the lives of patients with genetic disorders.